Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 505 participants.
Also called NCT02294474
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 505 participants
- Sponsor
- Registry
-
NCT02294474 -
2014-002844-42
-
- Other papers using this trial's data
- Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Chile, Colombia, Germany, Hungary, Italy, Romania, Russia, South Korea, Spain, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT02294474. Randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-02 (actual). Results posted on 2018-01-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
- Acronym
- SORELLA2
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- SAR342434
- Intervention (Drug)
- Humalog
- Intervention (Drug)
- insulin glargine HOE901
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02294474- Content hash
0333e46947be2e07b3f34b8094d2e548152e0e589b3b1ec33187ad84d3ea7bc9